Thoratec (THOR) Prelim. Q2 Revenue Tops Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. NKE

Go back to Thoratec (THOR) Prelim. Q2 Revenue Tops Expectations

Thoratec Announces Preliminary Second Quarter Revenue

July 22, 2015 7:05 AM EDT

PLEASANTON, Calif., July 22, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced preliminary unaudited revenue in the range of $128 million to $129 million for the second quarter of 2015.

"Our strong second quarter performance resulted from a broad increase in utilization of our products globally, driven in particular by favorable trends in our North American HeartMate franchise," said D. Keith Grossman, President and Chief Executive Officer.  "We continued to make progress with our commercial initiatives and... More

St. Jude Medical and Thoratec Announce Definitive Agreement

July 22, 2015 7:00 AM EDT

Combination Accelerates Innovation-Based Growth Program and Expands Heart Failure Franchise

St. Jude Medical Will Discuss Transaction on its Second Quarter 2015 Earnings Call Scheduled for 8 a.m. EDT (7 a.m. CDT) on July 22, 2015

ST. PAUL, Minn. & PLEASANTON, Calif.--(BUSINESS WIRE)-- St. Jude Medical (NYSE: STJ) and Thoratec (NASDAQ: THOR) today announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a... More